NEW VIRUS VARIANTS THREATEN BIDEN PANDEMIC PLANS — The Biden administration is rushing to prevent the spread of new strains of the coronavirus that scientists worry could be more transmissible or render vaccines less effective. The government is collaborating with Moderna to develop vaccine booster shots aimed at strains first identified in South Africa and the United Kingdom. Preliminary research on Moderna’s Covid-19 vaccine suggest the shot is less potent, but still effective, against a strain first found in South Africa — leading the company to develop a booster shot “out of an abundance of caution,” said CEO Stéphane Bancel. “We’re trying to stay a step ahead of the game, rather than waiting for something to happen and reacting,” Anthony Fauci, director of the National Institutes of Allergy and Infectious Disease, which is working with Moderna, told POLITICO. The U.S. has detected 195 cases of the U.K. variant and one case, first reported on Monday in Minnesota, of a variant originating in Brazil. There have been no confirmed cases of the South African variant in the United States so far. Biden campaigned on quickly reining in the virus, but since taking office has emphasized the difficulties that his team faces — warning it is contending with a series of pressing health and logistical challenges, Adam Cancryn and I write. In the meantime, it’s unclear how quickly Moderna’s booster shots — if effective — could move through the regulatory chain. Chief Medical Officer Tal Zaks said on an investor call Monday that the company has not had that conversation with FDA just yet, but that slightly varied annual flu shots could provide a precedent. FDA says it has “already given thought to developing a potential pathway, should changes need to be made to authorized COVID-19 vaccines or other products based on information on emerging variants.” MERCK ABANDONS COVID VACCINES — Drug giant Merck is ending work on potential Covid-19 vaccines after weak results from early trials, it said Monday. The company will stop development of two potential shots because the immune responses they produced in Phase I studies were weaker than those elicited by other Covid-19 vaccines and those seen in people infected with the virus, Lauren Morello writes. It’s the first major fail for a manufacturer that has received significant U.S. funding: The Biomedical Advanced Research and Development Authority gave Merck $38 million to develop its shots. Merck was one of the later entrants in the vaccine race after it announced the two candidates in May. Although Merck is walking away from Covid-19 vaccines, the company said it will continue to work on a pair of treatments for the virus. The company inked a $356 million deal with Warp Speed last year to provide the U.S. with up to 100,000 doses. PFIZER FINISHES TEEN VAX ENROLLMENT — Pfizer has enrolled more than 2,000 children ages 12-15 in a study of its Covid-19 vaccine, a company spokesperson said last Friday. On its heels is Moderna, also trying to enroll adolescents but lagging after slow enrollment during the holidays, Maura Turcotte reports. More than 2.8 million children and young adults between 0 to 24 years old had confirmed cases of Covid-19 last year, according to CDC reports. It has big implications. Data from both the Pfizer and Moderna trials could determine when children and teens may finally get the jab. On Wednesday, the CDC's Advisory Committee on Immunization Practices will meet to discuss Covid-19 clinical trials in children. BD TOUTS ANTIGEN-TEST STUDY — Diagnostics manufacturer BD is the latest to argue rapid antigen tests are highly accurate at catching people who are capable of spreading virus that can grow in cell culture, pointing to a recent study published in the journal Clinical Infectious Diseases. The study examined 251 people within seven days of the onset of Covid-19 symptoms. “By providing a more relevant test to identify individuals that are likely to be shedding infectious virus and therefore transmit SARS-CoV-2, we will be in a better position to contain its spread,” BD vice president of medical affairs Charles Cooper said in a press release. |